SSY Group's Vitamin A palmitate approved as drug in China
SSY Group Limited announced today that its Vitamin A Palmitate has received registration approval from China's National Medical Products Administration. This approval allows the product to be marketed as a bulk drug for pharmaceutical preparations in China. Vitamin A Palmitate is primarily used in fat-soluble vitamin injections.
The company's board of directors made this voluntary announcement to keep shareholders and potential investors informed of the latest business development. The announcement was released from Hong Kong on November 27, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when SSY Group publishes news
Free account required • Unsubscribe anytime